Generic assay capabilities aren't enough. Each therapeutic area requires disease-specific model systems, validated biomarkers, and scientific expertise that understand the nuance of the disease biology.
Tell us the indication, mechanism, and translational biomarker strategy. We will recommend disease-relevant models and assay endpoints.
Comprehensive oncology programs spanning targeted therapies, immuno-oncology, and combination strategies. Our platforms encompass solid and hematological malignancies with patient-derived model systems for translational relevance.
Key Indication AreaSpecialized CNS pharmacology platform with expertise in neuronal cell models, blood-brain barrier penetration studies, and mechanistic characterization of neurological disease targets.
Key Indication AreaIntegrated cardiometabolic research capabilities including primary cardiac cell systems, metabolic flux analysis, and NASH/NAFLD translational models for cardiometabolic disease programs.
Key Indication AreaAdvanced immune cell profiling, cytokine network analysis, and autoimmune disease modeling. Our platforms support the full spectrum of inflammatory targets from innate to adaptive immune mechanisms.
Key Indication AreaAntiviral, antibacterial, and antifungal drug discovery support with BSL-2 certified capabilities, resistance profiling, and host-directed therapy evaluation platforms.
Key Indication AreaPrecision support for rare disease programs including patient-derived iPSC models, gene therapy vector characterization, and biomarker development for diseases with limited patient populations.
Key Indication AreaBring us the program question, constraints, and next decision point. We will map the right assays, controls, timeline, and reporting package before the first plate is run.
